BIOPHYTIS SA SP/ADR by Biophytis SA (BPTSY)

About BIOPHYTIS SA SP/ADR by Biophytis SA (BPTSY)

Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 27, 2006 and is headquartered in Paris, France.

BIOPHYTIS SA SP/ADR by Biophytis SA News